Related Experiment Video

Updated: Nov 26, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.0K

The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors

Matthew H Taylor1, Emmett V Schmidt2, Corina Dutcus3

  • 1Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA.

Future Oncology (London, England)
|December 10, 2020
PubMed

Insights

Lenvatinib plus pembrolizumab shows promising antitumor activity and durable responses in solid tumors. This combination therapy offers a potential new treatment option for cancers with limited therapeutic choices.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Tumor progression and immune evasion are driven by complex signals in the tumor microenvironment.
  • Combined blockade of VEGF and immune checkpoints can enhance anti-tumor immunity.
  • Preclinical models suggest synergistic effects of dual blockade strategies.

Purpose of the Study:

  • To evaluate the safety and efficacy of lenvatinib plus pembrolizumab in patients with various solid tumors.
  • To assess the antitumor activity and response durability of this combination regimen.
  • To explore a novel therapeutic approach for advanced solid cancers.

Main Methods:

  • The LEAP clinical trial program is investigating lenvatinib (multikinase inhibitor) and pembrolizumab (PD-1 inhibitor).
  • The study includes multiple ongoing trials across diverse solid tumor types.
  • Safety and efficacy data are being collected from participants.

Main Results:

  • Preliminary results indicate robust antitumor activity across different tumor types.
  • Durable responses have been observed in patients treated with the combination.
  • The safety profile of lenvatinib plus pembrolizumab is manageable.

Conclusions:

  • Lenvatinib plus pembrolizumab demonstrates significant potential as a new treatment regimen.
  • This combination offers a promising option for solid tumors with unmet therapeutic needs.
  • Further investigation is warranted to establish its role in cancer therapy.
Keywords:
LEAP programcombination therapylenvatinibpembrolizumabsolid tumors

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.4K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
290
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
888